Showing results (921-930 of 3,354) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|June 22, 2019
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind studyGeorgina V Long, Reinhard Dummer, Omid Hamid, et al.
The Lancet. Oncology|June 22, 2019
MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trialSepideh Saadatmand, H Amarens Geuzinge, Emiel J T Rutgers, et al.
The Lancet. Oncology|February 13, 2022
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 studyPaul G Richardson, Aurore Perrot, Jesus San-Miguel, et al.
The Lancet. Oncology|June 5, 2019
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trialElisa A Rozeman, Alexander M Menzies, Alexander C J van Akkooi, et al.
The Lancet. Oncology|October 12, 2019
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 studyRina Hui, Mustafa Özgüroğlu, Augusto Villegas, et al.
The Lancet. Oncology|September 30, 2021
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 studyJuan W Valle, Arndt Vogel, Crystal S Denlinger, et al.
The Lancet. Oncology|September 30, 2021
Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extensionTimothy J Kendall, Max Robinson, Daniel J Brierley, et al.
The Lancet. Oncology|October 8, 2021
Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study
The Lancet. Oncology|October 8, 2021
Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trialHongyan Cheng, Liju Zong, Yujia Kong, et al.
The Lancet. Oncology|October 17, 2021
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trialDean A Fennell, Sean Ewings, Christian Ottensmeier, et al.
Pageof 336